KPTI
Karyopharm Therapeutics Inc
NASDAQ: KPTI · HEALTHCARE · BIOTECHNOLOGY
$8.31
-1.07% today
Updated 2026-04-30
Market cap
$195.22M
P/E ratio
—
P/S ratio
1.34x
EPS (TTM)
$-17.80
Dividend yield
—
52W range
$4 – $11
Volume
1.0M
Karyopharm Therapeutics Inc (KPTI) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-134.20%
Operating margin
-52.40%
ROE
-891.00%
ROA
-41.60%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | $152000.00 | $-10.31M | 100.00% | -6,783.55% | -6,783.55% |
| 2012 | $634000.00 | $-15.89M | -2,123.19% | -2,506.31% | -2,505.99% |
| 2013 | $387000.00 | $-33.95M | 100.00% | -8,772.61% | -8,771.83% |
| 2014 | $229000.00 | $-75.78M | -26,156.33% | -33,120.52% | -33,090.39% |
| 2015 | $250000.00 | $-118.18M | 100.00% | -47,630.40% | -47,272.40% |
| 2016 | $154000.00 | $-109.58M | 100.00% | -71,903.90% | -71,153.90% |
| 2017 | $1.60M | $-128.98M | 100.00% | -8,133.21% | -8,036.39% |
| 2018 | $30.34M | $-178.41M | -431.95% | -592.97% | -588.10% |
| 2019 | $40.89M | $-199.59M | 94.11% | -462.85% | -488.08% |
| 2020 | $108.08M | $-196.27M | 97.50% | -159.00% | -181.59% |
| 2021 | $209.82M | $-124.09M | 98.38% | -46.84% | -59.14% |
| 2022 | $157.07M | $-165.29M | 96.68% | -90.53% | -105.23% |
| 2023 | $146.03M | $-143.10M | 96.62% | -88.71% | -97.99% |
| 2024 | $145.24M | $-76.42M | 95.86% | -82.24% | -52.62% |
| 2025 | $146.07M | $-196.04M | 95.93% | -62.10% | -134.21% |